treatment News

AUSTIN, Texas — Luminex Corporation (NASDAQ: LMNX), the worldwide leader in multiplexed solutions, today announced that it has launched two new cystic fibrosis (CF) tests in Europe, the xTAG® Cystic Fibrosis 39 Kit v2 and xTAG® Cystic Fibrosis 71 Kit v2, as CE IVD Marked products under the European Directive...
Lyme disease is emerging in Canada, and is expected to increase with climate change, but effective, enhanced surveillance and clinician awareness will be key to minimizing the impact of the disease, write researchers in a review in CMAJ (Canadian Medical Association Journal) http://www.cmaj.ca/press/pg1221.pdf (www.cmaj.ca). Lyme disease is transmitted by ticks...
Hopes that a malaria vaccine could be widely available by 2012 have risen with the start last week (26 May) of phase III trials of the world’s most advanced candidate. Five infants in Bagamoyo, Tanzania, have received GlaxoSmithKline’s RTS,S vaccine and 16,000 children aged two and under will receive the...
CONFIRM is the largest prospective study (n=300) conducted in patients with HRS-1, a life-threatening and acute form of advanced liver disease with high unmet needs and a poor prognosis — DUBLIN – Mallinckrodt Plc, a global biopharmaceutical company, today announced the publication of results from its pivotal Phase 3 CONFIRM...
I blog, I tweet and I use Facebook. And as I recently told a medical colleague, social media has been an enormously useful tool in my work. “I can barely keep up with e-mail,” he snorted back. “I’m not about to open up that black box.” About 15 years ago,...
SAN FRANCISCO — Medivation, Inc. (Nasdaq: MDVN) today announced the completion of patient enrollment in the CONNECTION study, a six-month, confirmatory, pivotal Phase 3 trial of the investigational drug dimebon in patients with mild-to-moderate Alzheimer’s disease. The international, double-blind, placebo-controlled, pivotal Phase 3 study enrolled 598 patients, exceeding the enrollment...
LOS ANGELES — MEDomics, LLC (www.medomics.com) announces an innovative test for early diagnosis of mitochondrial diseases, a group of disorders that can result in neurological dysfunction, muscle weakness, gastrointestinal symptoms, migraine headaches, blindness, deafness, and diabetes. The MEDomics mitochondrial genome test, MitoDx(TM), uses the revolutionary NextGen sequencing technology to detect...
SAN DIEGO – MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing potential new therapies for cancer, and Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies, today announced...
DARMSTADT, Germany – Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced topline data from the Phase II [email protected] BTC 047 study evaluating bintrafusp alfa as a monotherapy in the second-line treatment of patients with locally advanced or metastatic biliary tract cancer (BTC) who have failed or are intolerant...